Literature DB >> 19917056

Mature acinar cells are refractory to carcinoma development by targeted activation of Ras oncogene in adult rats.

Hajime Tanaka1, Katsumi Fukamachi, Mitsuru Futakuchi, David B Alexander, Ne Long, Shojiro Tamamushi, Kohtaro Minami, Susumu Seino, Hirotaka Ohara, Takashi Joh, Hiroyuki Tsuda.   

Abstract

Pancreatic ductal adenocarcinoma (PDA) is one of the most debilitating malignancies in humans. A thorough understanding of the cytogenesis of this disease will aid in establishing successful treatments. We have developed an animal model which uses adult Hras(G12V) and Kras(G12V) transgenic rats in which oncogene expression is regulated by the Cre/loxP system and neoplastic lesions are induced by injection of adenovirus-expressing Cre recombinase. When adenovirus with Cre recombinase under the control of the CMV enhancer/chicken beta-actin (CAG) promoter (Ad-CAG-Cre) is injected into the pancreatic duct of these animals, pancreatic neoplasias develop. Pathologically, the origin of these lesions is duct, intercalated duct, and centroacinar cells, but not acinar cells. The present study was undertaken to test the effect of acinar cell-specific oncogenic ras expression. Adult transgenic rats were injected with adenovirus with Cre recombinase under the control of the acinar cell-specific promoters amylase (Ad-Amy-Cre) and elastase-1 (Ad-Ela-Cre) or under the control of the non-specific CAG promoter. Injection of either Ad-Amy-Cre or Ad-Ela-Cre into the pancreatic ducts of transgenic animals in which oncogenic Kras is tagged with hemagglutinin (HA), HA-Kras(G12V) rats resulted in expression of oncogenic ras in acinar cells but not in duct, intercalated duct, or centroacinar cells. Notably, injected animals did not develop any observable proliferative or neoplastic lesions. In marked contrast, injection of Ad-CAG-Cre resulted in pancreatic cancer development within 4 weeks. These results indicate that adult acinar cells are refractory to Ras oncogene activation and do not develop neoplasia in this model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917056     DOI: 10.1111/j.1349-7006.2009.01410.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  5 in total

1.  Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence.

Authors:  Carmen Guerra; Manuel Collado; Carolina Navas; Alberto J Schuhmacher; Isabel Hernández-Porras; Marta Cañamero; Manuel Rodriguez-Justo; Manuel Serrano; Mariano Barbacid
Journal:  Cancer Cell       Date:  2011-06-14       Impact factor: 31.743

2.  Establishment of a pancreatic cancer animal model using the pancreas-targeted hydrodynamic gene delivery method.

Authors:  Osamu Shibata; Kenya Kamimura; Yuto Tanaka; Kohei Ogawa; Takashi Owaki; Chiyumi Oda; Shinichi Morita; Atsushi Kimura; Hiroyuki Abe; Satoshi Ikarashi; Kazunao Hayashi; Takeshi Yokoo; Shuji Terai
Journal:  Mol Ther Nucleic Acids       Date:  2022-03-28       Impact factor: 10.183

3.  Rat N-ERC/mesothelin as a marker for in vivo screening of drugs against pancreas cancer.

Authors:  Katsumi Fukamachi; Masaaki Iigo; Yoshiaki Hagiwara; Koji Shibata; Mitsuru Futakuchi; David B Alexander; Okio Hino; Masumi Suzui; Hiroyuki Tsuda
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.240

4.  Evaluation of a biomarker for the diagnosis of pancreas cancer using an animal model.

Authors:  Katsumi Fukamachi; Yoshiaki Hagiwara; Mitsuru Futakuchi; David B Alexander; Hiroyuki Tsuda; Masumi Suzui
Journal:  J Toxicol Pathol       Date:  2019-04-04       Impact factor: 1.628

5.  CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A.

Authors:  Q Tu; J Hao; X Zhou; L Yan; H Dai; B Sun; D Yang; S An; L Lv; B Jiao; C Chen; R Lai; P Shi; X Zhao
Journal:  Oncogene       Date:  2017-09-11       Impact factor: 9.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.